Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $17.00 Consensus Target Price from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has been given an average rating of "Buy" by the nine analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $17.00.

Several equities analysts recently weighed in on the stock. StockNews.com upgraded shares of Voyager Therapeutics from a "hold" rating to a "buy" rating in a report on Monday. Leerink Partnrs upgraded shares of Voyager Therapeutics to a "strong-buy" rating in a report on Wednesday, October 16th. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Canaccord Genuity Group reiterated a "buy" rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, Wedbush cut their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating on the stock in a report on Wednesday, August 7th.

Insider Transactions at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the transaction, the insider now owns 86,001 shares of the company's stock, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.53% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VYGR. ProShare Advisors LLC bought a new position in Voyager Therapeutics in the first quarter valued at $101,000. Vanguard Group Inc. grew its position in shares of Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company's stock valued at $30,087,000 after acquiring an additional 702,030 shares during the period. Ameritas Investment Partners Inc. grew its position in shares of Voyager Therapeutics by 49.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company's stock valued at $37,000 after acquiring an additional 1,300 shares during the period. American International Group Inc. grew its position in shares of Voyager Therapeutics by 22.9% in the 1st quarter. American International Group Inc. now owns 19,397 shares of the company's stock valued at $181,000 after acquiring an additional 3,610 shares during the period. Finally, Lazard Asset Management LLC grew its position in shares of Voyager Therapeutics by 95.3% in the 1st quarter. Lazard Asset Management LLC now owns 18,742 shares of the company's stock valued at $174,000 after acquiring an additional 9,146 shares during the period. Institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Stock Up 4.2 %

NASDAQ VYGR traded up $0.23 during trading hours on Friday, hitting $5.66. The company's stock had a trading volume of 359,880 shares, compared to its average volume of 640,424. The stock has a fifty day moving average of $6.55 and a 200 day moving average of $7.42. Voyager Therapeutics has a twelve month low of $5.19 and a twelve month high of $11.72. The firm has a market capitalization of $309.18 million, a P/E ratio of 7.97 and a beta of 0.89.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same period in the prior year, the business posted ($0.59) earnings per share. On average, analysts predict that Voyager Therapeutics will post -1.03 earnings per share for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.